Figure 7.

AICAR and metformin treatments alleviate olfaction defects and reduce Aβ aggregation. (A) Chemotaxis responses of wild-type adults and adults with pan-neuronal expression of Aβ1-42 or Q40 to IAA and 2-nonanone, following treatment with AICAR or metformin. Data from three or more independent experiments are presented as mean ± s.e.m. P values are derived from two-way ANOVA with Dunnett's multiple comparisons test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; no asterisk indicates not significant. (B, C) Fibril Aβ levels (B) and total Aβ levels (C) in worms treated with of AICAR or metformin were measured using a dot blot assay with. Total Aβ levels remained unchanged with treatments, but fibril Aβ levels decreased significantly. Aβ densitometry was quantified on the right. N = 4, Data are presented as mean ± s.e.m. P values are derived from one-way ANOVA with Dunnett's multiple comparisons test. **P < 0.01; ***P < 0.001.